Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report</li></ul>

MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report

MIRA: Solid Balance Sheet for Promising Company

MIRA: Raising Price Target on Study Results

MIRA: Quick Phase I Design Completion Bodes Well

<ul><li>MIRA Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia.</li><li> The company announced it is in advanced discussions with a top cancer hospital to study Ketamir-2 for the treatment of cancer-related pain and depression.</li></ul>

MIRA Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. The company announced it is in advanced discussions with a top cancer hospital to study Ketamir-2 for the treatment of cancer-related pain and depression.

MIRA: In Advanced Discussions with Major Potential Partner

United States

Mira Pharmaceuticals, Inc. operates as a biotech company. The Company develops prescription drug to target the CB1 and CB2 receptors for chronic pain and anxiety without the impurities of marijuana or its side effects such as increased appetite and paranoia. Mira Pharmaceuticals serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mira Pharmaceuticals (MIRA US)

MIRA: Solid Balance Sheet for Promising Company

MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report

Zacks Small Cap Research

MIRA: Solid Balance Sheet for Promising Company

MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report

Zacks Small Cap Research

MIRA: Raising Price Target on Study Results

MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report

Zacks Small Cap Research

MIRA: Quick Phase I Design Completion Bodes Well

MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report

Zacks Small Cap Research

MIRA: In Advanced Discussions with Major Potential Partner

MIRA Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)